A Study to Determine the Effects of MK0557 in Obese Subjects (0557-006)(COMPLETED)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00533598
Recruitment Status : Completed
First Posted : September 21, 2007
Last Update Posted : September 7, 2016
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
The purpose of this study is to assess the effects of MK0557 on body weight in obese subjects.

Condition or disease Intervention/treatment Phase
Obesity Drug: MK0557 Phase 2

Study Type : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Study Start Date : September 2002
Actual Primary Completion Date : June 2003
Actual Study Completion Date : June 2003

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   21 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women between 21 and 65 years of age, willing to avoid all prescription and nonprescription medicine to alter body weight for entire study

Exclusion Criteria:

  • You are or plan to become pregnant
  • You have smoked or used nicotine within 6 months of the study
  • History of abusing alcohol and/or drugs
  • History of a stroke, you have diabetes mellitus, you are taking medication for high blood pressure, you have had recent surgery, you have been involved in another study within 3 months of study, use of cholesterol or anti-seizure medication during the study
  • Have participated in a weight loss program 3 months before the study or during the course of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00533598

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Medical Monitor Merck Sharp & Dohme Corp.

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00533598     History of Changes
Other Study ID Numbers: 0557-006
First Posted: September 21, 2007    Key Record Dates
Last Update Posted: September 7, 2016
Last Verified: September 2016